Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 526 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 526 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total value of $14,486.04. Following the completion of the transaction, the chief executive officer now directly owns 1,048,729 shares in the company, valued at approximately $28,881,996.66. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Trading Up 0.8 %

ELVN traded up $0.21 during mid-day trading on Thursday, hitting $25.51. 308,043 shares of the stock were exchanged, compared to its average volume of 262,300. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $27.67. The firm’s fifty day moving average is $23.19 and its two-hundred day moving average is $21.84. The company has a market cap of $1.20 billion, a PE ratio of -12.82 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its holdings in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth $9,657,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics in the second quarter valued at about $4,489,000. Baker BROS. Advisors LP purchased a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on ELVN. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.